Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis
Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu et autres
jp (code pays fourni par la source)
0 citations
JTO Clinical and Research Reports